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Increased COUP-TFII expression in adult hearts
induces mitochondrial dysfunction resulting in
heart failure
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Mitochondrial dysfunction and metabolic remodelling are pivotal in the development of
cardiomyopathy. Here, we show that myocardial COUP-TFII overexpression causes heart
failure in mice, suggesting a causal effect of elevated COUP-TFII levels on development of
dilated cardiomyopathy. COUP-TFII represses genes critical for mitochondrial electron
transport chain enzyme activity, oxidative stress detoxiﬁcation and mitochondrial dynamics,
resulting in increased levels of reactive oxygen species and lower rates of oxygen
consumption in mitochondria. COUP-TFII also suppresses the metabolic regulator PGC-1
network and decreases the expression of key glucose and lipid utilization genes, leading to a
reduction in both glucose and oleate oxidation in the hearts. These data suggest that COUP-
TFII affects mitochondrial function, impairs metabolic remodelling and has a key role in
dilated cardiomyopathy. Last, COUP-TFII haploinsufﬁciency attenuates the progression of
cardiac dilation and improves survival in a calcineurin transgenic mouse model, indicating that
COUP-TFII may serve as a therapeutic target for the treatment of dilated cardiomyopathy.
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H
eart failure is the leading cause of death in developed
countries, and dilated cardiomyopathy (DCM) is the most
common form of heart failure1. The aetiology for the
majority of non-ischaemic DCM remains unclear. Studies on
human specimens and animal models suggest that impaired
mitochondrial electron transport chain (ETC) reduces production
of high-energy phosphates2–4, leading to energy starvation of the
cells. Although the mitochondrial ETC primarily produces ATP,
it also generates reactive oxygen species (ROS) as part of a normal
respiration process5. A defective ETC has been linked to excessive
production of ROS6, which imposes oxidative stress in failing
hearts by damaging mitochondrial DNA and proteins and
triggering more ROS formation7. In addition, mitochondrial
dynamics also contribute to mitochondrial homeostasis in
the hearts. Impairment of mitochondrial fusion by Mfn1/Mfn2
double knockout (DKO) results in mitochondrial fragmentation,
respiratory dysfunction, leading to a rapid development of DCM8.
Metabolic remodelling also emerges as a major player in
pathogenesis of heart failure. We have proposed that metabolic
remodelling precedes, initiates and sustains functional and
structural remodelling9. The PGC-1 regulatory network is
known as the major network-modulating cardiac metabolism.
This network comprises coregulators PGC-1a and PGC-1b that
coactivate multiple nuclear receptors, including estrogen-related
receptor (ERR)a, ERRg and peroxisome proliferator-activated
receptor (PPAR)a, to control expression of genes essential for
energy and mitochondrial homeostasis10–13. Loss of key members
in this regulatory network produces a range of metabolic defects,
including heart failure, defective mitochondrial biogenesis and
dynamics and maladaptation to cardiac stress in mice10–13.
COUP-TFII (Nr2f2), a member of the nuclear receptor family,
is highly expressed in the embryonic atria14, whereas its
expression in ventricular cardiomyocytes remains very low from
embryo to adult14,15. Under pathological conditions, the
expression of COUP-TFII is elevated in the stressed
ventricles of non-ischaemic cardiomyopathy patients and a
pressure overload mouse model16,17.
In the present study, we generated a mouse model by
ectopically expressing COUP-TFII in adult cardiomyocytes to
understand the role of COUP-TFII in the development of
cardiomyopathy. Increased COUP-TFII levels alter expression of
key mitochondrial and metabolic genes, enhance oxidative stress,
disturb metabolic homeostasis and lead to DCM. On the other
hand, reduced COUP-TFII expression partially mitigates calci-
neurin-induced cardiac dysfunction and improves survival of
calcineurin transgenic mice. Our results reveal the causative role
of COUP-TFII in the development of heart failure.
Results
Increased COUP-TFII expression in stressed hearts. When we
reviewed available human DCM data sets, we found a signiﬁcant
increase in COUP-TFII expression levels (3.2-fold) in 13 myo-
cardial tissues of end-stage non-ischaemic DCM16 (Fig. 1a). In a
second cohort of patients, an average of 1.8-fold increase on
COUP-TFII levels was also observed in the heart of 86 patients
with idiopathic DCM (GSE5406)18. Results from these two
independent cohorts of patients suggest an association between
the ventricular COUP-TFII levels and DCM in human.
We found that in response to stress imposed by transaortic
constriction (TAC), the expression of ventricular COUP-TFII
mRNA was induced in mice (Supplementary Fig. 1a). This result is
consistent with previous ﬁndings of increased COUP-TFII protein
levels in this model17. Similarly, ventricles of calcineurin transgenic
mice (CnTg), known to develop hypertrophy and subsequent
DCM, also exhibited an elevated expression of the COUP-TFII
gene (Supplementary Fig. 1b). In addition, COUP-TFII protein
levels were increased in isolated cardiomyocytes of CnTg mice
(Supplementary Fig. 1c). Together, these results implicate a strong
association of increased COUP-TFII expression with
cardiomyopathy in mice and in humans.
COUP-TFII induces DCM. The potential link to cardio-
myopathy prompted us to investigate whether increased
COUP-TFII expression in mice might impact the development of
contractile dysfunction. For this purpose, we crossed a previously
established COUP-TFII overexpression allele CAG-S-COUP-TFII
with a cre driver Myh6-MerCreMer (Myh6-MCM) line14,19 to
overexpress COUP-TFII speciﬁcally in cardiomyocytes after
heart development is complete, by administration of tamoxifen
(Fig. 1b). Functionally, overexpressing COUP-TFII (OE,
Myh6-MCM; CAG-S-COUP-TFII) in 2-month-old mice resulted
in a greatly enlarged heart in comparison with the CTRL
(Myh6-MCM) mice (Fig. 1c) 16 days after COUP-TFII transgene
induction (D16). Echocardiography further revealed that OE
mice exhibited characteristics of DCM, including increased left
ventricular interior dimension (Fig. 1d and Supplementary
Fig. 1e), reduced fractional shortening (Fig. 1e) and decreased
relative wall thickness (RWT; Supplementary Fig. 1f, right panel).
The progressive compromise of cardiac function resulted in
increased mortality of OE mice after activation of COUP-TFII
expression (Fig. 1f). Notably, day 16 OE hearts also had a 5.3-fold
increase of COUP-TFII mRNA levels over CTRL (Supplementary
Fig. 1g). By this time, the OE hearts exhibited severe dilation and
contractile dysfunction analogous to end-stage DCM in human
patients. The overexpressed COUP-TFII mRNA levels between
human specimens (3.2X, Fig. 1a) and OE hearts (5.3X,
Supplementary Fig. 1g) are not too far apart, suggesting that
the mouse model is relevant. Most importantly, the activated
COUP-TFII transgene increases COUP-TFII protein levels in
cardiomyocytes (Supplementary Fig. 1d) to a similar extent as
CnTg does (Supplementary Fig. 1c), which gives us conﬁdence to
use this model for dissecting the role of COUP-TFII in
cardiomyopathy. In summary, our animal model shows that
increased COUP-TFII expression in the heart is sufﬁcient to
induce DCM with a high mortality rate.
At the molecular level, OE ventricles exhibited decreased
aMHC, increased bMHC and reduced SERCA2a gene expression
(Supplementary Fig. 1h), similar to the molecular changes
observed in human DCM patients and other mouse models. To
gain insights on COUP-TFII’s effect in hearts, we identiﬁed the
molecular proﬁle of day 16 OE hearts through microarray
analysis using ventricular compartments. Unbiased Gene
Ontology analysis of the OE proﬁle showed signiﬁcant enrich-
ment in the category of ‘DCM’ in the Kyoto Encyclopedia of
Genes and Genomes (P¼ 2.2 10 4), further supporting the
pivotal role of COUP-TFII in DCM. Moreover, using the OE
proﬁle as a transcriptomic signature of COUP-TFII activities, we
found that the COUP-TFII signature is considerably higher in the
DCM patients than the CTRL group (Fig. 1g). This ﬁnding
suggests a stronger presence of COUP-TFII activities in DCM
hearts as a result of higher levels of COUP-TFII expression
(Fig. 1a). Collectively, our data reveal that the COUP-TFII
signalling also exists in the human hearts and is positively
correlated with a pathological proﬁle of DCM.
Mechanistically, the Ingenuity Pathway analysis reveals
‘mitochondrial dysfunction’, ‘fatty acid b-oxidation’ and
‘glycolysis’ as the most prominent pathways affected by
COUP-TFII overexpression in cardiomyocytes (Fig. 1h). This
result suggests that COUP-TFII alters cardiac energy homeostasis
via modulating expression of genes important for energy
production, fuel utilization and mitochondrial function.
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Impaired cardiac fuel utilization. The OE proﬁle shows a
signiﬁcantly reduced expression of many genes that controls fuel
utilization. Quantitative reverse transcription–PCR (qRT–PCR)
analysis revealed that genes for uptake, binding, trafﬁcking into
the mitochondria and oxidation of fatty acids all exhibited a
reduced expression in OE hearts as early as day 4 (Fig. 2a). These
ﬁndings suggest that fatty acid utilization may be limited in the
OE hearts. Indeed, the OE hearts exhibited a lower oleate oxi-
dation rate ex vivo (Fig. 2b), as predicted by the molecular proﬁle
of the OE hearts.
A comprehensive analysis of the genes implicated in glucose
usage of OE hearts showed decreased mRNA levels of Glut4, Hk2
and Pfkm (Fig. 2a) genes required for glucose uptake, phosphor-
ylation and subsequent glycolysis, respectively. These ﬁndings
suggest that OE hearts are also defective in glucose utilization.
This was corroborated by the reduced glucose oxidation rates in
ex vivo OE hearts (Fig. 2c). Interestingly, we also observed an
increase in the expression of a subset of genes in the glycolytic
pathways (Fig. 2a). However, these changes, which may be a
compensatory effect, were not able to offset the impairment in
glucose utilization. The reduced fatty acid and glucose oxidation
rates are accompanied with decreased oxygen consumption rate
(OCR) in the OE hearts (Fig. 2d), suggesting a defect in oxidative
phosphorylation for energy production.
The PGC-1 network is critical in regulating genes essential for
cardiac metabolism10,13. Because the expression of PGC-1a is
upregulated in the adipose tissue of COUP-TFII heterozygous
mutant mice20, it is likely that PGC-1a expression is also altered
when COUP-TFII is overexpressed in the hearts. Indeed, PGC-1a
expression was reduced when COUP-TFII is overexpressed
(Fig. 2a). Moreover, levels of other members of the PGC-1
network, including PGC-1b, ERRa, ERRg and PPARa are all
reduced in cardiac tissues in the OE hearts (Fig. 2a). The notion
that COUP-TFII suppresses the PGC-1 network is supported by
the inverse relationship of COUP-TFII and PGC-1a/b11, ERRa21
and PPARa22 signatures (Supplementary Fig. 2). These results
indicate that COUP-TFII is a major metabolic regulator that is
central to control cardiac fuel metabolism.
Because PGC-1a is a direct downstream target of COUP-TFII
in adipocytes20, it is likely that the same regulatory mechanism
also operates in the heart. Using chromatin immunoprecipitation
(ChIP)-quantitative PCR (qPCR) assays, we found that
COUP-TFII indeed binds to a previously identiﬁed intronic
COUP-TFII-binding site in adipocytes (Fig. 2e)20. This result
conﬁrms that PGC-1a is likely a direct target of COUP-TFII in
the heart and that the mechanism of action by which COUP-TFII
regulates PGC-1a is conserved among various cell types. In
addition to PGC-1a, COUP-TFII also directly binds to ERRa,
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Figure 1 | Myocardial COUP-TFII expression causes dilated cardiomyopathy (DCM). (a) COUP-TFII mRNA levels in human heart tissues of non-failing
(NF, n¼ 6) and idiopathic DCM (n¼ 13) from GSE1869. (b) Strategy of inducible COUP-TFII expression in adult mouse myocardium. (c) Gross view of day
16 hearts. The scale of rulers underneath the whole mount images is 1mm. (d,e) Time-coursed echocardiogram. Day 0 indicates the day before induction of
COUP-TFII expression. LVIDd, left ventricular interior dimension at diastole. N¼ 5 (CTRL) and 7 (OE). (f) Survival rate of nine CTRL and eight OE mice over
time. (g) Manifestation of the COUP-TFII gene signature in human heart samples (GSE1869). COUP-TFII gene signature is curated from all COUP-TFII
downstream targets in mouse hearts that are identiﬁed by the microarray analysis. (h) Major biological processes altered by COUP-TFII overexpression
identiﬁed by the Ingenuity pathway analysis. ***Po0.001 (t-test) between CTRL and OE. Error bars denote the standard error of the mean (s.e.m.).
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ERRg and PPARa genes in ChIP assays (Fig. 2e). Collectively, our
results indicate a direct regulatory role of COUP-TFII for these
master metabolic regulators.
Development of mitochondrial dysfunction. We next examine
whether mitochondria are dysfunctional in the OE hearts, based
on downregulation of the expression of many genes that encode
components in complexes I, II, III and IV of the mitochondrial
ETC (Fig. 3a). Transcript analysis further conﬁrmed suppression
of ETC gene expression 9 days post induction of COUP-TFII
expression when the OE hearts are at the early phase of heart
failure (Supplementary Fig. 3a). The effect of altered ETC gene
expression is manifested in the reduction of enzyme activities of
complexes I, II, III and IV in isolated mitochondria of OE
ventricles (Fig. 3b). This defect on ETC enzyme complexes may
generate excessive production of ROS and increase oxidative
stress. In addition, decreased expression of mitochondrial ROS
scavenger gene Sod2 in the OE hearts (Fig. 3a and Supplementary
Fig. 3a) may reduce the ROS detoxifying capacity and contribute
to an increase in ROS levels. In line with this gene expression
proﬁle, higher levels of oxidized proteins were observed in
mitochondria of day 9 OE hearts in the Oxyblot assay (Fig. 3c).
As a result, mitochondrial protein function is compromised in the
OE hearts, as reﬂected in the reduction of mitochondrial
aconitase activity, which is highly sensitive to oxidative stress
(Fig. 3d). Control experiments carried out in a reduced condition
reveal that, without the impact of oxidation, total aconitase
activities are comparable between CTRL and OE mice, suggesting
excessive oxidation as the primary cause of reduction in enzyme
activities. The consequence of heightened oxidative stress is
manifested in a decreased mitochondrial OCR (Fig. 3e) and a
lower mitochondrial ATP content (Supplementary Fig. 3b) sug-
gesting a reduction in oxidative phosphorylation capacity and
ATP production in mitochondria of the day 9 OE hearts. Notably,
the number and density of mitochondria are comparable between
OE and CTRL hearts, as indicated by the similar mitochondria
DNA content and volume density (Supplementary Fig. 3c,d,
respectively). It is not surprising that mitochondrial number and
density are not altered in response to decreased PGC-1a and
PGC-1b levels, because Martin et al. already reported similar
observations in adult PGC-1a/b DKO hearts11. Perhaps the rate
of mitochondria biogenesis slows down at the adult stage,
rendering the effect of losing PGC-1a/b less pronounced as
compared with the perinatal period where mitochondria rapidly
propagate. Thus, our ﬁndings indicate that decreased ATP
production in mitochondria because of increased oxidative
stress, rather than the change of mitochondrial numbers, is one
of the major contributors of the defective energy metabolism
observed in the OE heart.
To conﬁrm that the observed alterations of the mitochondrial
metabolism in the heart are caused by COUP-TFII overexpres-
sion and are not secondary to heart failure, we examine the
expression of COUP-TFII target genes in earlier time point before
onset of heart failure. Day 4 is likely the earliest time point for
induction of COUP-TFII expression subsequent to 3-day
treatment of tamoxifen before the exhibition of defects in the
heart function. As anticipated, echocardiogram results indeed
show no signiﬁcant difference in ventricular chamber size, wall
thickness and ejection fraction between CTRL and OE hearts
(Supplementary Fig. 3e–g), indicating that day 4 OE hearts are
structurally and functionally comparable to CTRLs. Results of
qRT–PCR analyses on day 4 hearts reafﬁrm that suppression
of gene expression by COUP-TFII precedes the development of
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gross differences between genotypes (Fig. 3f). Moreover, we also
ﬁnd enhanced recruitment of COUP-TFII to the genomic loci of
Ndufs1, Ndufs6, Ndufaf4, Sdha and Sod2 genes by ChIP assays in
the day 4 OE hearts (Fig. 3g), corroborating the notion that
COUP-TFII is likely to directly regulate the expression of these
genes. Importantly, the mitochondrial respiration rate is also
lower in day 4 OE hearts than that of CTRLs (Supplementary
Fig. 3h), consistent with the COUP-TFII-dependent changes of
gene expression. Taken together, our data demonstrate that
regulation of mitochondrial gene expression and function by
COUP-TFII occurs at the time when OE hearts are structurally
and functionally similar to the CTRL hearts. These ﬁndings are
indicative of the facts that dysregulation of mitochondrial
function in the OE mice is a result of COUP-TFII signalling
rather than a secondary consequence of heart failure.
Interestingly, we found that mitochondria of day 9 OE hearts
exhibit a roundish shape with reduced electron density and
increased distance between cristae (Fig. 4a), suggesting an
accumulation of unhealthy mitochondria. Consistent with the
morphological ﬁndings, we observed a reduction in the expres-
sion of key mitochondrial dynamics genes in OE hearts, including
Pink1 for removal of damaged mitochondria and Opa1, Mfn1 and
Mfn2 for fusion and regeneration of healthy mitochondria
(Fig. 4b and Supplementary Fig. 4a), whereas no changes were
seen in the expression of ﬁssion genes Fis1, Mff and Dnm1l
(Supplementary Fig. 4a). Furthermore, protein levels of Pink1,
Mfn1 and Mfn2 were reduced in isolated cardiomyocytes of OE
hearts at the early failing stage (day 9, Supplementary Fig. 4b),
indicating that COUP-TFII may directly control the expression of
these genes. The reduced expression of Pink1 and Mfn2, two
of three major members of the mitochondrial quality control
pathway23,24, in the OE hearts may disrupt the mitochondrial
dynamics and contribute to the accumulation of damaged
mitochondria as seen in the electron micrograph (Fig. 4a).
Collectively, these ﬁndings suggest that increased COUP-TFII
perturbs mitochondrial homeostasis through suppressing the
expression of mitochondrial dynamics genes.
Results from ChIP-qPCR assays further reveal in vivo binding
of COUP-TFII on genomic loci of the mitochondrial dynamics
genes Pink1, Opa1 and Mfn2 of adult hearts (Fig. 4c), suggesting
that these genes are direct targets of COUP-TFII. Next, we used a
conserved COUP-TFII-binding site of the Pink1 gene as an
example to demonstrate direct regulation of Pink1 by COUP-TFII
through these cis-acting elements. This COUP-TFII-binding site
is located between 93 and 105 base pairs upstream of the
transcription start site, within a stretch of highly conserved
nucleotides between human and mouse. This site is surrounded
by open chromatin as evident by the high DNaseI sensitivity
(Fig. 4d). A stretch of conserved nucleotides from this region that
contain the wild-type (Pink1_WT) or mutant (Pink1_mu)
COUP-TFII-binding sites was cloned in front of a TATA-
promoter-driven luciferase reporter for luciferase assay in C2C12
cells. The COUP-TFII-binding site shows reduced reporter
activities compared with that of the mutant site (Fig. 4e),
suggesting a repressive role in the regulation of Pink1 gene
expression. Taken together, the results indicate that binding
of COUP-TFII at genomic loci represses expression of
mitochondrial dynamics genes.
The COUP-TFII regulatory network in human. The pivotal role
of COUP-TFII in regulation of mitochondrial and metabolic
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genes observed in mice, here, also occurs in human, as supported
by publicly available data from patient specimens (Fig. 5).
COUP-TFII activity was scored and ranked in RNA proﬁles
of 102 human ventricles (GSE5406) based on the mouse
COUP-TFII gene signature (Fig. 5, top panel). A higher
COUP-TFII signature indicates a stronger COUP-TFII activity in
a sample. We ﬁrst observed a positive and signiﬁcant correlation
between COUP-TFII levels and activities in these human samples
(Fig. 5). This result supports the notion that the COUP-TFII
regulatory network identiﬁed in mice also operates in the human
heart. In addition, there is a positive correlation between
COUP-TFII activity and levels of a cardiac stress marker Nppb
(Fig. 5), suggesting that increased COUP-TFII signalling may be
associated with cardiac stress in human hearts, consistent with
what we observed in multiple mouse models.
By comparing COUP-TFII activities and the expression levels
of genes of interest, we found signiﬁcant and inverse correlations
between COUP-TFII activities and levels of many mitochondrial
genes that encode ETC enzymes, including 23 complex I, 4
complex II and 6 complex III genes (Fig. 5). Moreover, levels of
mitochondrial dynamics genes MFN2, OPA1 and PINK1 are also
negatively correlated with COUP-TFII activities (Fig. 5). These
ﬁndings are consistent with an essential role of COUP-TFII in
suppression of mitochondrial functions and homeostasis in
patients.
Similarly, inverse correlations were found between COUP-TFII
activities and levels of energy metabolic genes, including fatty acid
catabolic genes FABP3, MLYCD, ACADVL, ACADM, ACADS
and ACAA2, glucose metabolic genes SLC2A4, PFKM, LDHB and
PDK2, and major metabolic regulators ERRa, ERRg and PPARa
(Fig. 5). The compensatory effect of increasing expression of the
glycolytic gene ENO1 is also observed in the human heart (Fig. 5),
further supporting the presence of a conserved regulatory
mechanism for cardiac metabolism. In summary, expression of
energy metabolism genes is suppressed when COUP-TFII levels
are elevated in the human hearts.
COUP-TFII reduction attenuates disease progression. The
calcineurin transgenic mice develop DCM25 and expression of
COUP-TFII is elevated in these mice (Supplementary Fig. 1b,c).
We therefore utilized this model to test whether reducing
COUP-TFII dosage ameliorates disease progression. The
COUP-TFII ﬂoxed and Myh6-MerCreMer alleles were bred into
the CnTg background to allow genetic removal of one copy of the
COUP-TFII gene in cardiomyocytes in 7-week-old animals
through tamoxifen-induced, cre recombinase-mediated gene
excision (Fig. 6a). The majority of mice carrying the calcineurin
transgene in a COUP-TFIIﬂox/þ background (CnTg; COUP-
TFIIﬂox/þ , CnTg/Fþ ) exhibit an accelerated rate of sudden death
after 12 weeks of age, when compared with mice of CTRL groups
COUP-TFIIﬂox/þ (Fþ ) and Myh6-MerCreMer; COUP-TFIIﬂox/þ
(Cre/Fþ ) shown in Fig. 6b. Removing one copy of the COUP-TFII
gene in cardiomyocytes in the calcineurin transgenic background
(CnTg; Myh6-MerCreMer; COUP-TFIIﬂox/þ , CnTg/Cre/Fþ )
substantially reduces COUP-TFII protein levels (Supplementary
Fig. 5a) and leads to an increase in overall survival rate when
compared with the CnTg/Fþ group over a 20-week period
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(Fig. 6b). This demonstrates that lowering COUP-TFII dosage
prolongs survival under intense cardiac stress.
Echocardiography imaging before the removal of one copy of
COUP-TFII (6 weeks old) and post-removal (12 weeks old) was
performed to examine structural and functional alterations of the
heart. The choice of the 12-week time point is based on previous
observations that CnTg mice exhibited DCM by 12 weeks25, and
that the transient cardiac effect exerted by tamoxifen diminished
1 month after treatment26. Mice carrying the calcineurin
transgene already developed eccentric hypertrophy at 6 weeks,
before the treatment (Supplementary Fig. 5b,c), consistent with
previous ﬁndings25. Both CnTg/Fþ and CnTg/Cre/Fþ mice
exhibit thicker left ventricular walls (Supplementary Fig. 5b) and
increased left ventricular interior dimensions (Supplementary
Fig. 5c), when compared with corresponding Fþ and Cre/Fþ
CTRL groups, respectively. At 12 weeks of age, the CnTg/Fþ
mice develop DCM, exhibiting a greatly increased inner chamber
size (Fig. 6c) and reduced RWT (Fig. 6d), compared with CTRL
groups of the same age or within the group at age of 6 weeks
(Fig. 6c,d and Supplementary Fig. 5c). In contrast, removal of an
allele of COUP-TFII in CnTg/Cre/Fþ mice partially suppresses
the dilation (Fig. 6c), and they maintain RWT levels similar to
that of 6-week-old mice (Fig. 6d). This result suggests that hearts
of calcineurin transgenic mice in which one copy of COUP-TFII is
removed are still able to compensate for stress via a hypertrophic
response rather than progressing towards DCM. However,
removal of just one copy of COUP-TFII failed to rescue the
declining contractility (Supplementary Fig. 5d). Taken together,
our results indicate that reducing COUP-TFII dosage is able to
improve survival rates in stressed hearts by partially attenuating
the disease progression towards DCM.
Discussion
Hearts of DCM exhibit mitochondrial dysfunction4,27, which are
proposed to increase oxidative stress, compromise high-energy
phosphate production and eventually lead to contractile
dysfunction1. Normally, oxidative phosphorylation produces
ROS as a by-product, which are removed by endogenous
antioxidants in healthy mitochondria. However, dysfunctional
mitochondria may generate excessive ROS to trigger and augment
cellular oxidative stress, and lead to pathogenesis of heart
failure6,28,29. In the present study, we found that adult hearts
with elevated COUP-TFII levels produce excessive ROS in the
mitochondria. The excessive ROS inﬂict damages on
mitochondria, as evidenced by structural abnormality, decreased
activities of oxidation-sensitive aconitase and reduced OCRs,
eventually leading to contractility reduction and chamber
dilation. Our ﬁndings are in line with previous studies that
demonstrate the key role of excessive mitochondrial ROS
production in the development of cardiac dysfunction. For
example, increasing ROS levels by knocking out Sod2, a principal
ROS scavenger located in mitochondrial matrix, leads to heart
failure30. Conversely, normalizing mitochondrial ROS levels
by administering synthetic Szeto-Schiller peptide SS-31 or
mitochondrial targeted catalase in hearts ameliorates stress-
induced cardiac dysfunction31,32. Thus, our study links increased
COUP-TFII expression, as observed in a subset of DCM patients,
to excessive ROS production in adult hearts.
Functioning as a transcription factor, COUP-TFII regulates
multiple genes that control mitochondrial ROS levels. COUP-
TFII represses expression of many ETC genes in both direct and
indirect manners, resulting in decreased activities of ETC enzyme
complexes. Modiﬁcations of ETC complexes have been shown to
disturb electron transportation along the ETC and divert
electrons to oxygen for excess ROS production6,33,34. Therefore,
our ﬁndings suggest that COUP-TFII-mediated ETC defects
promote ROS production. At the same time, COUP-TFII
overexpression also compromises the endogenous antioxidant
capacity by directly repressing the Sod2 gene. Collectively, the
increased oxidative stress observed in COUP-TFII overexpression
hearts is likely the result of the combined effect of increased ROS
production and decreased ROS detoxiﬁcation.
Mitochondrial dynamics emerge as an important mechanism
in maintaining normal cardiac function by revitalizing mito-
chondria35. The phenotypic resemblance between COUP-TFII
OE and Mfn1/Mfn2 DKO mice8 suggests that mitochondrial
fusion defects may be an important player in COUP-TFII-
induced heart failure. The faster development of aberrant
mitochondrial morphology in COUP-TFII OE as compared
withMfn1/Mfn2 DKO mice (16 days versus 3 weeks, respectively)
further suggests that other players may also contribute to our
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phenotype. The reduced expression of mitochondrial inner
membrane fusion gene Opa1 in the OE hearts could be part of
the explanation, as Opa1 deﬁciency confers a mitochondrial
dysfunction phenotype as strong as the combined deﬁciency
of Mfn1 and Mfn2 in MEF cells36. In addition, increased COUP-
TFII may impair mitochondrial quality control that depends on
the Pink1-Mfn2 pathway24,37. Previous studies show that loss of
Pink1 or Mfn2 results in mitochondrial dysfunction, increased
ROS production and cardiomyopathy24,38,39. Thus, the reduced
levels of Pink1 and Mfn2 in the OE hearts might lead to
pathological accumulation of damaged mitochondria that further
contribute to the increase of ROS production.
Transcriptional regulation of mitochondrial ETC genes by the
PGC-1 network has been previously reported10–13 and our results
place COUP-TFII upstream of this network. Importantly, we now
show that COUP-TFII can directly modulate expression of key
ETC genes, indicating that COUP-TFII utilizes two layers
of regulating mechanisms to control the essential machinery
for oxidative phosphorylation. These COUP-TFII-dependent
regulatory mechanisms ﬁnd further support in the analyses of
human specimens, in which COUP-TFII activities inversely
correlate with mRNA levels of multiple ETC genes as well as
ERRa, ERRg and PPARa, whereas failing hearts exhibit higher
COUP-TFII and lower PGC-1/ERR activities40. Notably, PGC-1a
has been shown to serve as an upstream regulator in promoting
Sod2 expression41, and is negatively regulated by COUP-TFII in
the hearts. These ﬁndings suggest that COUP-TFII may also
compromise the ROS detoxifying system through suppressing the
PGC-1a-Sod2 pathway.
Impaired cardiac energy homeostasis is a salient feature of
heart failure42. In response to a variety of stresses, hearts
switch fuel substrate preference from fatty acids to carbohydrates
and its proposed mechanism is alteration of expression of cardiac
metabolic genes43,44. Emerging evidence reveals that failing hearts
suffer impairment in this substrate selection ﬂexibility1,45–47. In
our mouse model, increased COUP-TFII reduced fatty acid
oxidation and reduced glucose usage. This phenotype may be
attributed to repressed expression of the PGC-1 network genes
and key glucose utilization genes Glut4, Hk2 and Pfkm by
COUP-TFII. Collectively, our COUP-TFII OE mice exhibit a
cardiac metabolic phenotype that resembles loss of ﬂexibility of
substrate selection in advanced DCM. We propose that alteration
of expression of key genes for both fatty acid and glucose
metabolism by COUP-TFII underlies the development of the
metabolic inﬂexibility.
In summary, our data indicate that overexpression of COUP-
TFII in hearts results in defects in ETC, accumulation of damaged
mitochondria and reduced mitochondrial ROS scavenging
capacity. All these defects result in the accumulation of oxidative
stress and eventually lead to heart failure. Importantly, alterations
of gene expression are already observed at day 4 when OE and
CTRL hearts are structurally and functionally similar to
each other. Therefore, the observable phenotypes are due to
COUP-TFII, not secondary to heart failure.
Methods
Animals. Mice carried CAG-S-COUP-TFII allele and COUP-TFII ﬂox allele were
described previously14,48. The cardiomyocyte-speciﬁc, tamoxifen inducible cre
driver Myh6-MerCreMer (Myh6-MCM)19 and calcineurin transgenic mice
Tg(Myh6-Ppp3ca)25 were acquired from the Jackson Laboratory (Stock number
009075). All animals used here are male and are between 2 and 4 months old unless
otherwise indicated. All animal experiments adhered to the Guidelines of the
Institutional Animal Care and Use Committee of the Baylor College of Medicine
and were conducted within the scope of approved animal protocols.
qRT–PCR. Reverse transcription reactions were carried out using the Transcriptor
First Strand cDNA Synthesis kit (Roche, 04379012001) to make cDNA according
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to the manufacturer’s guide. Quantitative PCR (qPCR) analysis was performed on
Applied Biosystems StepOnePlus using the FastStart Universal SYBR Green Master
Mix (Roche, 04913850001) or the Taqman Universal master Mix II (Invitrogen,
4440040). Each cycle of the qPCR consists of 95 C, 15 s, for denaturing and 60 C,
60 s, for annealing and extension with total 40 cycles performed. Primer sequences
are included in Supplementary Table 1.
Antibodies. Anti-COUP-TFII antibodies are purchased from Perseus Proteomics
(H7147, 1:2,000 dilution) or from Cell Signaling (#6434, 1:1,000 dilution). The
Pink1 antibody is from Abcam (ab23707, 1:1,000 dilution). The Mfn1 antibody is
from Abcam (ab57602, 1:500 dilution). The Mfn2 antibody is from Abcam
(ab56889, 1:500 dilution). The Hsp60 antibody is from BD Transduction (#611563,
1:5,000 dilution).
Cell line. C2C12 (ATCC CRL-1772) are acquired from American Type Culture
Collection.
Expression array analysis. Whole ventricles were collected from 2-month-old
animals comprising three Myh6-MCM and three Myh6-MCM; CAG-S-COUP-TFII
mice. RNA extraction was performed using Trizol and Qiagen RNeasy according to
the manufacturer’s guides. Affymetrix mouse genome 430 2.0 chips were used in
this study. The BCM Genomic and RNA Proﬁling Core Lab performed the probe
generation and subsequent microarray hybridization on Affymetrix mouse genome
430 2.0 chips. Acquired raw data were ﬁrst processed by the GeneSpring GX
software using RMA as the summarization algorithm, Quantile for normalization
and median of all samples for baseline transformation. The resulting entity list was
ﬁltered on expression (50.0–35272.484) in raw data followed by statistical analysis
using one-way analysis of variance with corrected P value cutoff at 0.05, asymptotic
for P value computation and Benjamini–Hochberg for multiple testing correction.
Calculated against the CTRL atria group, entities from the mutant atria and
CTRL ventricles having absolute fold change greater than 1.2 were considered
differentially expressed. The entity lists were subsequently annotated using
Affymetrix annotation and analysed by Ingenuity Pathways Analysis (Ingenuity
Systems). The NCBI accession number for the expression array study reported in
this paper is GSE63759.
The publicly available human array data sets GSE1869 and GSE5406 were
scored for manifestation of the mouse model-derived COUP-TFII gene signature,
using published methods49. A gene signature score (also known as a ‘t-score’) was
deﬁned for each external proﬁle as the two-sided t-statistic comparing, within the
proﬁle, the average of the COUP-TFII-induced genes with the average of the
COUP-TFII-repressed genes. In this way, the t-score contrasted the patterns of the
‘COUP-TFII-induced’ genes against those of the ‘COUP-TFII-repressed’ genes,
could be used to derive a single value denoting coordinate expression of the two
gene sets. Where multiple probes in GSE5406 referred to the same gene, the probes
with the highest variation was taken to represent the gene; genes were then centred
to standard deviations from the median across sample proﬁles. Expression patterns
were visualized as heat maps using Java TreeView50. We analysed data from
non-ischaemic failing hearts primarily because of the scope of the present study.
For GSE1869, we used data from 6 ‘nonfailing’ and 13 ‘Nonischemic, Pre-LVAD
Patient group’ hearts for analysis. We exclude the ‘Nonischemic, No-LVAD Patient
group’ because the expression proﬁle of this group exhibits similar pattern with the
nonfailing group16. For GSE5406, we used data from 16 ‘human nonfailing
LV myocardium’ samples and 86 ‘human failing LV myocardium, Idiopathic’
specimens for analysis.
Mitochondrial respiration assay. XF24 extracellular ﬂux analyzer from Seahorse
Biosciences was used to measure the rates of oxygen consumption. Mitochondria
were isolated from appropriate tissue by homogenization in mitochondrial
isolation buffer using a Dounce homogenizer (Kontes) ﬁltered through cheesecloth,
and centrifuged at 1,500 g, then 9,000 g. XF24 cartridge was equilibrated with the
calibration solution overnight at 37 C. XF assay buffer (70mM sucrose, 220mM
mannitol, 10mM KH2PO4, 5mM MgCl2, 2mM HEPES, 1mM EGTA, 0.2% BSA,
10mM pyruvate and 5mM malate) was prepared and pH adjusted to 7.2 on the
day of the experiment. XF assay buffer was used to prepare mitochondrial assay
reagents, 2.5mM ADP, 2 mM oligomycin, 4 mM FCCP, 4 mM antimycin (ﬁnal
concentration). All the reagents were loaded in the ports as suggested by Seahorse
Biosciences. OCRs were measured for 4min with 30 s of mixing and expressed as
pmolmin 1.
ETC activity assay. For enzymatic assays of respiratory chain complexes I–IV,
sufﬁcient amount of tissue or cells were collected. Potassium phosphate buffer
(25mM, pH 7.5) was added to a ﬁnal volume of 300 ml and the samples were
sonicated (5 s pulse x4, 60% power) using a Microson XL2000 Ultrasonic Cell
Disruptor (Misonix). For experiments on isolated mitochondria, the mitochondria
were also disrupted by sonication as described above. The spectrophotometric
kinetic assays were performed at 30 C in a volume of 175 ml using a
monochromator microplate reader (Tecan M200). Complex I activity
(NADH:ubiquinone oxidoreductase) was determined by measuring oxidation of
NADH at 340 nm (using ferricyanide as the electron acceptor) in a reaction
mixture of 25mM potassium phosphate (pH 7.5), 0.2mM NADH and 1.7mM
potassium ferricyanide. Complex II activity (succinate dehydrogenase) was
determined by measuring the reduction of the artiﬁcial electron acceptor
2,6-dichlorophenol-indophenol at 600 nm in a reaction mixture of 25mM
potassium phosphate (pH 7.5), 20mM succinate, 0.5mM 2,6-dichlorophenol-
indophenol, 10mM rotenone, 2 mgml 1 antimycin A and 2mM potassium
cyanide. Complex III activity (Ubiquinol/cytochrome c oxidoreductase) was
determined by measuring the reduction of cytochrome c at 550 nm in a reaction
mixture of 25mM potassium phosphate (pH 7.5), 35 mM reduced decylubiquinone,
15 mM cytochrome c, 10mM rotenone and 2mM potassium cyanide. Complex IV
activity (cytochrome c oxidase) was determined by measuring the oxidation of
cytochrome c at 550 nm in a reaction mixture of 10mM potassium phosphate
(pH 7.5) and 0.1mM reduced cytochrome c. Citrate synthase activity was
determined by measuring the reduction of 5,5’-dithiobis(2-nitrobenzoic acid) at
412 nm, which is coupled to the reduction of acetyl-CoA by citrate synthase in the
presence of oxaloacetate. The reaction mixture consists of 10mM potassium
phosphate (pH 7.5), 100mM 5,5’-dithiobis(2-nitrobenzoic acid), 50 mM acetyl-CoA
and 250 mM oxaloacetate. All activities were calculated as nmolmin 1 per mg
protein, and expressed as a percentage of control activity. Experiments were
performed on six independent samples for each genotype.
Aconitase assay. The activity of mitochondrial aconitase was measured on the
basis of conversion of citrate into a-ketoglutarate coupled with NADP reduction
(Sigma) and was normalized for total protein. Activity was measured in the native
state and after ‘reactivation’ by incubating mitochondria in ferrous ammonium
sulfate for 5min before performing the assay.
Echocardiogram. For transthoracic echocardiography, mice were anaesthetized
using 2% isoﬂurane in 95% O2. Body temperature was maintained on a heated
platform, and electrocardiogram and temperature were continuously monitored.
Cardiac function was assessed using a VisualSonics VeVo 770 Imaging System
(VisualSonics) equipped with high-frequency 30MHz probe.
Transaortic constriction. The TAC surgery was performed as described51 on adult
CD1 mice (strain code: 022, Charles River) of 8–10 weeks of age and between 20
and 25 g of weight. Mice were anaesthetized with isoﬂurane (2–3%, inhalation) in
an induction chamber and then intubated with a 20-G intravenous catheter and
ventilated with a mouse ventilator (Minivent, Harvard Apparatus, Inc).
Anaesthesia was maintained with inhaled isoﬂurane (1–2%). A longitudinal 5-mm
incision of the skin was made with scissors at midline of sternum. The chest cavity
was opened by a small incision at the level of the second intercostal space 2–3mm
from the left sternal border. While opening the chest wall, the chest retractor was
gently inserted to spread the wound 4–5mm in width. The transverse portion of
the aorta was bluntly dissected with curved forceps. Then, 6-0 silk was brought
underneath the transverse aorta between the left common carotid artery and the
brachiocephalic trunk. One 26-G needle was placed directly above and parallel to
the aorta. The loop was then tied around the aorta and needle, and secured with a
second knot. The needle was immediately removed to create a lumen with a ﬁxed
stenotic diameter. The chest cavity was closed by 6-0 silk suture. Sham-operated
mice underwent similar surgical procedures, including isolation of the aorta,
looping of aorta, but without tying of the suture. The pressure load caused by TAC
was veriﬁed by the pressure gradient across the aortic constriction measured by
echocardiography. Only mice with a pressure gradient 435mmHg were analysed
for cardiac hypertrophy, echocardiography and gene analysis.
Ex vivo cardiac metabolic analyses. Mice were anaesthetized with chloral hydrate
(400mg kg 1) and anticoagulated with heparin (50 IU, i.v.). Hearts were rapidly
excised, arrested in ice-cold Krebs–Henseleit buffer, and mounted on a
Langendorff apparatus. Hearts were then perfused retrogradely at an afterload
of 80 cm H2O with non-recirculating Krebs–Henseleit buffer containing glucose
(5mmol l 1), sodium oleate (0.4mmol l 1) bound to bovine serum albumin
(Probumin, EMD Millipore), [9,3-3H]oleate (0.2 mCiml 1), [U-14C]glucose
(0.1 mCiml 1) and insulin (40 mUml 1; Eli Lilly and Company). The
Krebs–Henseleit buffer was equilibrated with 95% O2–5% CO2 and maintained at a
constant temperature of 37 C. After an initial 30min stabilization, rates of oleate
and glucose oxidation were determined by quantitative collection of [3H]2O
and [14C]O2 from the coronary efﬂuent as previously reported52. Myocardial
oxygen consumption (MVO2; mmolmin 1) was calculated by measuring the
arterio-venous O2 content difference with an YSI 5300A biological oxygen monitor.
ChIP assay. ChIP analysis of fresh cardiac tissues was performed according to a
protocol published in the Nature Protocols53. Chromatin DNA complexes were
collected from mouse ventricles. The mouse monoclonal anti-FLAG antibody M2
(Sigma F1804) was used for the ChIP assay. DNA released from the precipitation
was subjected to qPCR analysis for quantiﬁcation of the presence of speciﬁc loci.
qPCR analysis was performed on Applied Biosystems StepOnePlus using the
FastStart Universal SYBR Green Master Mix (Roche, 04913850001). Each cycle of
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the qPCR consists of 95 C, 15 s, for denaturing and 60 C, 60 s, for annealing and
extension performed with total 40 cycles. Primer sequences are included in
Supplementary Table 1.
Oxyblot assay. The Oxyblot assay was perform on freshly isolated mitochondria
from ventricles by using the Oxyblot protein oxidation kit from Millipore (S7150)
according to the manufacturer’s guide.
Measurement of ATP content. ATP contents of isolated mitochondria were
assessed by the ATPlite kit from Perkin Elmer (6016943) according to the
manufacturer’s instruction, and normalized with protein contents.
Statistical tests. Two-tailed t-test is used for statistical analyses unless otherwise
indicated.
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